A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohortPeter Dubsky, Martin Filipits, LJ van't Veer et al.|ESMO Open|2021Cited by 16
Clinical applications of next‐generation sequencing‐based <scp>ctDNA</scp> analyses in breast cancer: defining treatment targets and dynamic changes during disease progressionEva Valentina Klocker, Michael Gnant, Christian F. Singer et al.|Molecular Oncology|2024Cited by 15
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Richard Greil, Daniel Egle et al.|Nature Cancer|2025Cited by 10
New Perspectives in the Management of Triple-Negative Breast CancerRupert Bartsch, Michael Gnant, Zsuzsanna Bagó-Horváth et al.|Breast Care|2025Cited by 3
123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)Gabriel Rinnerthaler, Richard Greil, Daniel Egle et al.|ESMO Open|2023Cited by 2